Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.

Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications. 

Register Now

Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.

Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.

Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Subspecialties

Close-up on StatLab’s portfolio and plans

May 2025—Despite its extensive portfolio and multiple manufacturing sites, simplicity seems to be at the heart of StatLab, thanks to its self-manufacturing approach. Four years ago, StatLab was primarily a distributor of medical products and manufacturer of a select few. Acquisitions, investment, and a change in the company’s profile came with new ownership, and the company, based in McKinney, Tex., is now “a full-fledged manufacturer across the entire histology portfolio,” says Joe Bernardo, chairman of the board of StatLab.

Granulomas on FNA: recognizing and ruling out malignancy

May 2025—Granulomas are organized clusters of immune cells that form as part of the body’s chronic inflammatory response, typically triggered by persistent antigens, chronic infections, or immune dysregulation. They develop when macrophages are activated, transforming into epithelioid histiocytes and multinucleated giant cells (MGC) in response to ongoing immune stimulation. Granulomas are usually surrounded by T lymphocytes, fibroblasts, and extracellular matrix components. While granulomas are most often associated with infections or autoimmune conditions like sarcoidosis, they can arise in a variety of other processes, including malignancy.

For myeloid malignancies, how WHO-HEM5 and ICC differ

May 2025—How the World Health Organization fifth edition of hematolymphoid tumors and the International Consensus Classification differ for myeloid malignancies was highlighted in cases presented in a CAP24 session last fall. Sanam Loghavi, MD, associate professor of pathology and laboratory medicine, Department of Hematopathology, University of Texas MD Anderson Cancer Center, spoke of myelodysplastic neoplasms/syndromes (MDS) with defining genetic abnormalities and the allelic state of TP53 in MDS, among other things. (Kamran M. Mirza, MD, PhD, of the University of Michigan, co-presented.)

Claudin 18.2: a new therapeutic target: What are the implications for cytopathologists?

May 2025—Claudin 18.2 (CLDN18.2), an isoform of claudin-18, is a transmembrane tight junction protein essential for maintaining barrier function and cell polarity in normal gastric and pancreatic epithelium. In malignant epithelial cells, the loss of polarity exposes the CLDN18.2 epitope, leading to its increased expression in gastric and pancreatic adenocarcinomas. CLDN18.2 has drawn attention as a therapeutic target, particularly with the development of the monoclonal IgG antibody zolbetuximab (Vyloy, Astellas Pharma). Zolbetuximab exerts its antitumor effects via both antibody-dependent and complement-mediated cytotoxicity and has demonstrated significantly improved progression-free and overall survival when combined with standard chemotherapy in two pivotal phase three clinical trials (SPOTLIGHT and GLOW). These data validated CLDN18.2 as a promising target in advanced, HER2-negative gastric and gastroesophageal junction (GEJ) adenocarcinoma.

The future of clinical laboratories in value-based care—Is this our tomorrow to lose?

April 2025—Many look to CAP TODAY to be a central disseminator of news, opinion, and other important information, and it has in the past filled that role in response to others’ requests. One such recent request is that of the Clinical Lab 2.0 movement, established in 2017 by the Project Santa Fe Foundation. We present here, for CAP TODAY readers, the Clinical Lab 2.0 movement’s position paper.

FIGO endometrial cancer staging, 2 years in

April 2025—Seen through the lens of metaphor, cancer staging is traffic control. Identify the biological crash, so to speak, and its severity; direct and redirect therapy; and try, ultimately, to unsnarl persistently risky crossings. That’s the sunny ideal. But efforts to improve traffic flow can also give rise to strong reactions, usually in words (if not a chorus of honking horns). Such is the case with the updated International Federation of Gynecology and Obstetrics staging system for endometrial cancer. FIGO 2023, by nearly all accounts, differs sharply from what had come before, incorporating molecular alterations, lymphovascular invasion, and tumor type and grade. Nearly two years later, it has yet to merge seamlessly into practice. “It definitely is controversial,” says Ekene Okoye, MD, associate professor of clinical pathology and genomic medicine, Department of Pathology and Genomic Medicine, Houston Methodist Hospital and Weill Cornell Medical College.

Not to be overlooked: lab administrative skill

April 2025—The transition from pathology training to practice is not just about diagnostic skill and confidence in that skill but also laboratory administrative duties, with experience in the latter harder to gain as a trainee.

Myeloid malignancies in WHO-HEM5 and ICC

April 2025—Speakers in a CAP24 session last fall spotlighted the differences between the WHO fifth edition of hematolymphoid tumors and the International Consensus Classification and set forth a framework for how to approach myeloid malignancy cases.

More gonorrhea resistance testing needed

April 2025—For Neisseria gonorrhoeae, the pipeline of antibiotics is running dry, and antimicrobial resistance is a global threat. “It’s just a matter of when it’s going to happen,” says Olusegun O. Soge, PhD, MSc, associate professor of global health and of medicine and adjunct associate professor of laboratory medicine and pathology at the University of Washington.

At the VHA, a mass-scale move to digital pathology

April 2025—Unprecedented moves with a lot of moving parts is how Jessica Wang-Rodriguez, MD, of the Veterans Health Administration describes a transition to digital pathology the size of the VHA’s. It’s a mission that has become necessary, Dr. Wang-Rodriguez says of the large-scale digital pathology transformation. She is executive director of the VHA National Pathology and Laboratory Medicine Program Office, Washington, DC, and professor of pathology at the University of California, San Diego.

MARKETPLACE

TRENDING